Paper Report for: Rungby_2009_Expert.Opin.Investig.Drugs_18_835
Reference
Title: Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes Rungby J Ref: Expert Opin Investig Drugs, 18:835, 2009 : PubMed
BI 1356, a xanthine-based DPP-4 inhibitor, has reached Phase III trials. The compound efficiently inhibits dipeptidyl peptidase 4 (DPP-4) in vitro and in vivo. In vivo GLP-1 levels increase to levels at or above the levels of other DPP-4 inhibitors. Preclinical trials suggest a once-daily administration of 5 mg to be efficient, long-lasting and without known side effects.
        
Related information
Citations formats
Rungby J (2009) Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes Expert Opin Investig Drugs18: 835-8